On this basis, we hypothesized that a treatment with agonistic anti-OX40 antibody alongside the TLR9 ligand, unmethylated CpG oligodeoxynucleotide will help to induce antitumor immune responses and eliminate established bladder tumor (MB49) and metastases as well. Here, TNFRSF4 is linked to urinary bladder neoplasm.